In fact, we hypothesize that IRAK4 inhibition might be most appropriate in early disease, a strategy that is supported by recent evidence demonstrating that around 40% of terminal bronchioles are already lost in patients with mild COPD (86). The gene discussed is IRAK4; the disease is chronic obstructive pulmonary disease.